Tagged with Novartis

Top 10 The top 10 companies in the world ranked by global orphan drug sales and market share in 2017. Swiss giants Novartis and Roche take the top two places, followed by American firm, Celgene. Made with Visme Infographic Maker

France Denis Delval, CEO of iconic French pharma firm LFB since December 2017, discusses his key priorities to build the new LFB.   My vision is that we should be strong enough to assume a leadership position in any space that we seek to participate in During his two terms at…

Switzerland Basel-headquartered pharma giant Novartis announced its financial results for 2018 this week, showcasing full year net sales growth of five percent driven by the strong performance of the company’s pharmaceutical business unit and some strategic divestments.   In 2018 we reimagined Novartis. We took major steps towards becoming a medicines company…

France The Top 20 pharma companies in France, ranked by total turnover at ex-manufacturer prices for 2018. Swiss giant Novartis is in first place with a EUR 2.6 billion turnover, a full 89 percent of which came from the retail market. In second place is local champion Sanofi with a turnover…

France Frédéric Collet, president Novartis France and general manager oncology explains the rationale behind Novartis’s consistent investment in France, the current shift in the company’s corporate culture and the main challenges inherent to the unprecedented wave of innovation that is revolutionizing the health industry.   In terms of research, we have invested EUR…

Turkey Dr. Altan Demirdere, president of Novartis Group in Turkey discusses the long history of Novartis and Sandoz in the country, as well as the current issues between the Turkish pharmaceutical industry and the government.   Through its Sandoz division, Novartis has been in Turkey since 1930 Can you introduce the…

Algeria Mourad Ishak, country president Novartis and general manager Sandoz Algeria reveals Novartis’ investment plan for local production, their “under one roof” project for the Novartis entities, and the key strategies to ensure sustainability within the Algerian market.   You’ve been in Algeria for four years. Can you enlighten our viewers…

UK The UK country managers of some of the biggest global pharma companies explain what it takes to manage in the UK market.   Erik Nordkamp, Pfizer Erik Nordkamp, the Dutch national serving as managing director of Pfizer UK and the newly-appointed president of the ABPI, likens managing a UK affiliate…

UK The Top 15 pharmaceutical companies in the UK in the year up to March 2018 according to IQVIA data, ranked by market share. Pfizer leads the way with a whopping 8.2% market share, followed by Novartis with 6% and GSK with 5.3%

Algeria Karim Harchaoui, country manager of Novartis Algeria, explains the rationale behind the recent restructuring of the Algerian affiliate, the evolution of the company’s local manufacturing footprint, and the strategic importance of Algeria to Novartis within the Africa and Middle East region.   Novartis has undergone an extensive restructuring of the…

Cancer Novartis receives NHS approval for their CAR T-cell therapy to treat leukaemia in children, 10 days after receiving European Commission (EC) approval. “It’s fantastic news for children and young people with this form of leukaemia.” Prof Charles Swanton, Cancer Research UK’s Dubbed as the future of cancer therapy, Kymriah, Novartis’ gene-modifying treatment…

Regulatory This week Novartis received approval from the European Commission (EC) for Kymriah, their chimeric antigen receptor T cell (CAR-T) therapy for young people under 25 with cancer of the blood. Leading the way in innovative cancer cures with an unrivalled portfolio of over 20 approved oncology medicines, Novartis is the only company in the…